179 related articles for article (PubMed ID: 1282105)
1. CR 2039, a new bis-(1H-tetrazol-5-yl)phenylbenzamide derivative with potential for the topical treatment of asthma.
Revel L; Colombo S; Ferrari F; Folco G; Rovati LC; Makovec F
Eur J Pharmacol; 1992 Dec; 229(1):45-53. PubMed ID: 1282105
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effect of HSR-6071, a new anti-allergic agent, on experimental asthma in rats and guinea-pigs.
Makino E; Ohashi T; Takahashi H; Kato H; Ito Y; Nagai H; Koda A; Azuma H
J Pharm Pharmacol; 1990 Apr; 42(4):236-41. PubMed ID: 1974289
[TBL] [Abstract][Full Text] [Related]
3. Antiallergic and cytoprotective activity of new N-phenylbenzamido acid derivatives.
Makovec F; Peris W; Revel L; Giovanetti R; Redaelli D; Rovati LC
J Med Chem; 1992 Oct; 35(20):3633-40. PubMed ID: 1433173
[TBL] [Abstract][Full Text] [Related]
4. Bronchoprotective effect of an intrabronchial administration of cilostazol powder and a nebulized PDE1 and PDE4 inhibitor KF19514 in guinea pigs.
Fujimura M; Tachibana H; Myou S; Kita T; Matsuda T
Int Arch Allergy Immunol; 1998 Jul; 116(3):220-7. PubMed ID: 9693270
[TBL] [Abstract][Full Text] [Related]
5. Anti-anaphylactic activity of the novel selective histamine H1 receptor antagonist mizolastine in the rodent.
Levrier J; Duval D; Prouteau M; Voltz C; Berry CN; Lloyd KG; Scatton B
Arzneimittelforschung; 1995 May; 45(5):559-68. PubMed ID: 7541995
[TBL] [Abstract][Full Text] [Related]
6. [Anti-allergic effects of tazanolast [butyl 3'-(1H-tetrazol-5-yl) oxanilate, WP-833] metabolites].
Hashimoto T; Edanami K; Naito A; Sano K; Fushimi H; Goto M
Nihon Yakurigaku Zasshi; 1990 Apr; 95(4):159-66. PubMed ID: 1695192
[TBL] [Abstract][Full Text] [Related]
7. Effect of SA-103 on experimental allergic models in vivo and in vitro--comparison with disodium cromoglycate.
Nabe T; Yamamura H; Kohno S; Ohata K
Arerugi; 1992 Jun; 41(6):676-85. PubMed ID: 1280084
[TBL] [Abstract][Full Text] [Related]
8. Effects of quinotolast, a new orally active antiallergic drug, on experimental allergic models.
Kobayashi K; Hiroi J; Kishi S; Sawase K; Hirayama Y; Chihara S; Imai T; Shigi Y; Shimomura K; Kohsaka M
Jpn J Pharmacol; 1993 Sep; 63(1):73-81. PubMed ID: 7505860
[TBL] [Abstract][Full Text] [Related]
9. Effect of 8-hexyloxy-3-(1H-tetrazol-5-yl)-2H-chromen-2-one [KP-136] on experimental asthma: a comparison with disodium cromoglycate.
Kuriyama K; Hiyama Y; Ito K
J Pharmacobiodyn; 1989 Mar; 12(3):175-81. PubMed ID: 2474641
[TBL] [Abstract][Full Text] [Related]
10. Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor.
Raeburn D; Underwood SL; Lewis SA; Woodman VR; Battram CH; Tomkinson A; Sharma S; Jordan R; Souness JE; Webber SE
Br J Pharmacol; 1994 Dec; 113(4):1423-31. PubMed ID: 7889300
[TBL] [Abstract][Full Text] [Related]
11. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent.
Yanni JM; Stephens DJ; Miller ST; Weimer LK; Graff G; Parnell D; Lang LS; Spellman JM; Brady MT; Gamache DA
J Ocul Pharmacol Ther; 1996; 12(4):389-400. PubMed ID: 8951675
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effect of aerosol administration of a sulfidopeptide leukotriene antagonist on bronchoconstriction induced by antigen inhalation in guinea pigs.
Bando T; Fujimura M; Shintani H; Saito M; Kurashima K; Nishi K; Matsuda T
Arzneimittelforschung; 1994 Jun; 44(6):754-7. PubMed ID: 8053975
[TBL] [Abstract][Full Text] [Related]
13. Antiallergic properties of an orally effective agent, [[3-(1H-tetrazol-5-yl)-phenyl] amino] oxoacetic acid n-butyl ester.
Agata M; Goto H; Tsuriya Y; Tachibana K; Kuroda T
Jpn J Pharmacol; 1982 Aug; 32(4):689-97. PubMed ID: 6182323
[TBL] [Abstract][Full Text] [Related]
14. [Experimental study on the action mechanism of a new bronchodilator agent, BB-1502].
Kamei H; Obi Y; Kawano K; Hirano M; Murata S; Imanishi H
Nihon Yakurigaku Zasshi; 1983 Nov; 82(5):335-42. PubMed ID: 6200410
[TBL] [Abstract][Full Text] [Related]
15. Antiallergic/antiasthmatic effect of novel antiallergic hexapeptide-95/220 in various experimental models.
Singh R; Nath A; Gupta PP; Shukla M; Khare SK; Kundu B
Indian J Exp Biol; 2001 Sep; 39(9):871-7. PubMed ID: 11831367
[TBL] [Abstract][Full Text] [Related]
16. Potent inhibitory activity of HSR-6071, a new antiallergic agent, on passive cutaneous anaphylaxis (PCA).
Makino E; Ohashi T; Takahashi H; Kato H; Ito Y; Nagai H; Koda A; Azuma H
Jpn J Pharmacol; 1990 Jan; 52(1):87-94. PubMed ID: 1689783
[TBL] [Abstract][Full Text] [Related]
17. In vivo anti-allergic and bronchopulmonary pharmacology of REV 3164 in rats and guinea-pigs.
Leibowitz M; Gordon RJ; Wolf PS; Sonnino-Goldman P
Arch Int Pharmacodyn Ther; 1984 Sep; 271(1):135-54. PubMed ID: 6497506
[TBL] [Abstract][Full Text] [Related]
18. CI-922--a novel, potent antiallergic compound--II. Activity in animal models of allergy.
Adolphson RL; Finkel MP; Robichaud LJ
Int J Immunopharmacol; 1987; 9(1):51-60. PubMed ID: 2438239
[TBL] [Abstract][Full Text] [Related]
19. Effect of butyl 3-(1H-tetrazol-5-Yl) oxanilate (MTB) on immunological or non-immunological histamine and SRS(-A) release from guinea-pig, monkey and human lung tissue.
Hashimoto T; Kohno SW; Ohata K; Yanagihara Y; Shida T
Jpn J Pharmacol; 1987 Aug; 44(4):447-53. PubMed ID: 2446036
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of immediate hypersensitivity reactions in laboratory animals by a phenanthroline salt (ICI 74,917).
Evans DP; Thomson DS
Br J Pharmacol; 1975 Mar; 53(3):409-18. PubMed ID: 48393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
